Skip to content

Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia

Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia:A Multicenter, Randomized, Double-blind, Sham-controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05289518
Acronym
RIC-SI
Enrollment
136
Registered
2022-03-21
Start date
2022-04-01
Completion date
2023-12-13
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

remote ischemic conditioning, acute ischemic stroke, insomnia

Brief summary

This study intends to further reveal the effect of RIC in stroke-related insomnia and explore its potential mechanisms.

Detailed description

Sleep disturbance after stroke is an important factor affecting the prognosis of stroke function. At present, most studies have focused on the diagnosis and treatment of sleep disordered breathing after stroke, while stroke-related insomnia has been neglected. Therefore, it is of great significance to explore a treatment that combines stroke protection with sleep improvement. Remote ischemic conditioning (RIC) triggers endogenous protective effect through transient and repeated ischemia in the limb to protect remote tissues and organs. The mechanisms of LRIC involve the regulation of autonomic nervous system, release of humoral factors, improvement of vascular endothelial function and modulation of immune/inflammatory responses, which participate in the regulation of sleep after stroke.Therefore, this study intends to conduct a randomized controlled trial to further reveal the effect of RIC in stroke-related insomnia and explore its potential mechanisms.

Interventions

RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 220mmHg and 5-min deflation.

The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.

Sponsors

Ji Xunming,MD,PhD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18 to 70 years old; * mRS≤3; * Meeting the DSM-IV diagnostic criteria for insomnia: in the past one month, the presence of any of the following symptoms: a. have difficulty falling asleep (sleep latency \>30 minutes); b. have trouble in maintaining sleep; c. early awakening, accompanied by impaired daytime function, with symptoms occurring more than three times a week, lasting at least 2 weeks; * Written informed consent provided by the patients or their legal relatives.

Exclusion criteria

* Chronic insomnia (PSQI≥8) or other sleep disorders was diagnosed 3 months before onset of stroke; * Presence or past history of neuropsychiatric diseases such as epilepsy, brain tumors, neurodegenerative disorders, restless leg syndrome, periodic leg movement; * Schizophrenia, significant anxiety and depression (HAMA≥14 points, HAMD≥17 points) with moderate to high suicide risk, etc; * Serious infection, malignancy, and other serious medical conditions (acute heart, liver, renal failure and other diseases); * Have taken any medications (antipsychotics, hypnotics, antidepressants, etc.) that interfere with sleep in the latest two weeks; * Have work shift or jet lag experience 4 months before enrollment Infants, Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
PSQI score(Pittsburgh sleep quality index)From baseline to 3monthsPSQI score of baseline and treatment after 1, 2, 3months . The the minimum value is 0, and the maximum value is 21.Higher scores mean a worse outcome.

Countries

China

Contacts

Primary ContactXunming Ji, MD, PhD
jixm@ccmu.edu.cn101-83199430
Backup ContactJin Ma, MD
2753297695@qq.com13699188306

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026